Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-03-26 7:11 pm Purchase | 2025-03-21 | 13G | Elevation Oncology, Inc. ELEV | BML Investment Partners L.P. | 5,890,934 9.900% | 5,890,934 (New Position) | Filing History |
| 2025-03-06 5:46 pm Purchase | 2025-02-28 | 13G | Kezar Life Sciences, Inc. KZR | BML Investment Partners L.P. | 368,594 5.100% | 368,594 (New Position) | Filing History |
| 2025-03-05 3:58 pm Unchanged | 2025-03-05 | 13D | Aadi Bioscience, Inc. AADI | BML Investment Partners L.P. | 2,435,000 4.980% | 0 (Unchanged) | Filing History |
| 2025-03-03 2:03 pm Purchase | 2025-02-26 | 13G | LAVA Therapeutics N.V. LVTX | BML Investment Partners L.P. | 1,958,110 7.400% | 1,958,110 (New Position) | Filing History |
| 2025-02-24 11:38 am Unchanged | 2025-02-24 | 13D | Aadi Bioscience, Inc. AADI | BML Investment Partners L.P. | 2,435,000 9.900% | 0 (Unchanged) | Filing History |
| 2025-02-14 11:03 am Purchase | 2025-02-11 | 13G | Third Harmonic Bio, Inc. THRD | BML Investment Partners L.P. | 3,724,167 8.200% | 3,724,167 (New Position) | Filing History |
| 2025-02-14 10:47 am Unchanged | 2024-12-31 | 13G | Ikena Oncology, Inc. IKNA | BML Investment Partners L.P. | 3,645,866 7.600% | 0 (Unchanged) | Filing History |
| 2025-02-14 10:26 am Purchase | 2024-12-31 | 13G | ESSA Pharma Inc. EPIX | BML Investment Partners L.P. | 4,221,546 9.500% | 38,323 (+0.92%) | Filing History |
| 2025-02-14 10:21 am Purchase | 2024-12-31 | 13G | Athira Pharma, Inc. ATHA | BML Investment Partners L.P. | 3,027,163 7.800% | 542,718 (+21.84%) | Filing History |
| 2025-02-14 10:15 am Purchase | 2024-12-31 | 13G | PMV Pharmaceuticals, Inc. PMVP | BML Investment Partners L.P. | 3,466,684 6.700% | 196,777 (+6.02%) | Filing History |
| 2025-02-14 10:06 am Unchanged | 2024-12-31 | 13G | PMV Pharmaceuticals, Inc. PMVP | BML Investment Partners L.P. | 3,269,907 6.300% | 0 (Unchanged) | Filing History |
| 2025-02-14 09:59 am Unchanged | 2024-12-31 | 13G | Athira Pharma, Inc. ATHA | BML Investment Partners L.P. | 2,484,445 6.500% | 0 (Unchanged) | Filing History |
| 2025-02-14 09:49 am Unchanged | 2024-12-31 | 13G | ESSA Pharma Inc. EPIX | BML Investment Partners L.P. | 4,183,223 9.400% | 0 (Unchanged) | Filing History |
| 2025-02-13 5:02 pm Unchanged | 2024-12-31 | 13G | Achilles Therapeutics plc ACHL | BML Investment Partners L.P. | 4,100,002 9.970% | 0 (Unchanged) | Filing History |
| 2025-02-13 4:41 pm Purchase | 2024-12-31 | 13G | Oramed Pharmaceuticals Inc. ORMP | BML Investment Partners L.P. | 2,643,907 6.550% | 595,273 (+29.06%) | Filing History |
| 2025-02-13 4:28 pm Unchanged | 2024-12-31 | 13G | AN2 Therapeutics, Inc. ANTX | BML Investment Partners L.P. | 5,749,432 19.200% | 0 (Unchanged) | Filing History |
| 2025-02-13 4:14 pm Purchase | 2024-12-31 | 13G | Instil Bio, Inc. TIL | BML Investment Partners L.P. | 440,000 6.700% | 93,810 (+27.10%) | Filing History |
| 2025-02-13 3:56 pm Sale | 2024-12-31 | 13G | Climb Bio, Inc. CLYM | BML Investment Partners L.P. | 0 0.000% | -2,350,682 (Position Closed) | Filing History |
| 2025-02-13 3:25 pm Purchase | 2024-12-31 | 13G | Adverum Biotechnologies, Inc. ADVM | BML Investment Partners L.P. | 2,373,404 11.400% | 167,058 (+7.57%) | Filing History |
| 2025-02-13 3:10 pm Unchanged | 2024-12-31 | 13G | Tectonic Therapeutic, Inc. TECX | BML Investment Partners L.P. | 0 0.000% | 0 (Unchanged) | Filing History |